Coagulation factor ix (recombinant), fc fusion protein - Biologic Drug Details

Summary for coagulation factor ix (recombinant), fc fusion protein

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for coagulation factor ix (recombinant), fc fusion protein

Recent Clinical Trials for coagulation factor ix (recombinant), fc fusion protein

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Syneos Health	Phase 3
Jiangsu Gensciences lnc.	Phase 2
Mansoura University	N/A

See all coagulation factor ix (recombinant), fc fusion protein clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for coagulation factor ix (recombinant), fc fusion protein Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for coagulation factor ix (recombinant), fc fusion protein Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Bioverativ Therapeutics, Inc.	ALPROLIX	coagulation factor ix (recombinant), fc fusion protein	For Injection	125444		2036-10-17	DrugPatentWatch analysis and company disclosures
Bioverativ Therapeutics, Inc.	ALPROLIX	coagulation factor ix (recombinant), fc fusion protein	For Injection	125444		2033-07-03	DrugPatentWatch analysis and company disclosures
Bioverativ Therapeutics, Inc.	ALPROLIX	coagulation factor ix (recombinant), fc fusion protein	For Injection	125444		2036-08-01	DrugPatentWatch analysis and company disclosures
Bioverativ Therapeutics, Inc.	ALPROLIX	coagulation factor ix (recombinant), fc fusion protein	For Injection	125444		2035-02-26	DrugPatentWatch analysis and company disclosures
Bioverativ Therapeutics, Inc.	ALPROLIX	coagulation factor ix (recombinant), fc fusion protein	For Injection	125444		2038-09-13	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for coagulation factor ix (recombinant), fc fusion protein Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

International Patents for coagulation factor ix (recombinant), fc fusion protein

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2016049873
Brazil	PI0411803
European Patent Office	3421488
Japan	5727420
Canada	3111881

Coagulation factor ix (recombinant), fc fusion protein Market Analysis and Financial Projection

Last updated: February 16, 2026

Market Dynamics and Financial Trajectory for Recombinant Coagulation Factor IX Fc Fusion Protein

Market Overview

Recombinant coagulation factor IX Fc fusion protein (rFIX-Fc) is a gene-engineered therapy for hemophilia B. It links factor IX to the Fc portion of immunoglobulin G (IgG), extending its half-life and reducing infusion frequency. The therapy aims to improve patient adherence and quality of life.

Key Market Drivers

• Increasing Hemophilia B Prevalence: Hemophilia B affects approximately 1 in 25,000 male births globally, estimated to impact nearly 40,000 patients worldwide.[1]
• Advances in Biologics: Longer half-life products like rFIX-Fc reduce infusion frequency from thrice weekly to once every 7-14 days. This enhances patient compliance.
• Regulatory Approvals and Launches: The first such product, eftrenonacog alfa (ALPROLIX), was approved by the FDA in 2014 and by the EMA in 2015. It has established a benchmark for upcoming products.[2]
• Pricing and Reimbursement: Biologic therapies command high prices, often exceeding $250,000 annually per patient. Reimbursement policies can influence market access.
• Growing Portfolio of Biosimilars: Entry of biosimilars and alternative therapies could pressure pricing, but high switching costs tend to favor innovator products.

Competitive Landscape

Product Name	Developer	Approval Year	Half-life Extension	Annual Cost (USD)*	Current Market Penetration
Eftrenonacog alfa (ALPROLIX)	Novo Nordisk	2014 (FDA)	5–7 days	>$250,000	Leading global market share
Damoctocog alfa pegol (Jivi)	Takeda	2018 (FDA)	10–14 days	Similar to ALPROLIX	Rapid adoption in advanced markets
Non-factor therapies (e.g. emicizumab)	Roche, others	2017–2020	Weekly or less	$400,000+ (non-factor)	Growing segment substituting traditional biologics

*Prices vary by region, healthcare system, and individual patient needs.

Market Size and Financial Projections

• Global Hemophilia B Market: Estimated at $300 million in 2022, projected to grow at a compound annual growth rate (CAGR) of 7% through 2030.[3]
• rFIX-Fc Segment: Expected to account for 40% of the hemophilia B biologic market by 2030 due to characteristics such as extended dosing intervals.

Year	Hemophilia B Market (USD)	rFIX-Fc Market Share	rFIX-Fc Revenue (USD)	Notes
2022	300 million	10%	30 million	Early commercialization phase
2025	450 million	20%	90 million	Increased adoption
2030	700 million	40%	280 million	Market penetration stabilizes

• Revenue Growth Factors: This includes improved patient loyalty, increased diagnosis rates, expansion into emerging markets, and potential formulation improvements.

Regulatory and Development Trends

• Regulatory Pathways: Both the FDA and EMA recognize the long-term benefits and safety profile of Fc fusion biologics, resulting in streamlined review processes.
• Pipeline Developments: Multiple biosimilars and next-generation Fc fusion proteins are under clinical evaluation. Expansion to gene therapy and non-factor options may influence long-term dynamics.

Risks and Challenges

• Pricing Pressures: Payers may limit access or negotiate discounts. Cost containment strategies could impact revenue.
• Biosimilar Competition: Entry of biosimilars may erode profit margins, though patent protections delay immediate competition in many regions.
• Delivery and Storage: Complex biologics require cold chain logistics and trained administration, posing challenges in low-resource settings.

Strategic Opportunities

• Market Expansion: Increasing awareness and diagnostics in Asia-Pacific and Latin America could generate new revenue streams.
• Combination Therapies: Combining Fc fusion proteins with other treatments to improve efficacy or patient convenience.
• Improved Formulations: Developing subcutaneous or longer-acting formulations to reduce treatment burden.

Key Takeaways

• The market for recombinant Fc fusion factor IX is growing steadily, underpinned by increasing hemophilia B prevalence, improved biologic properties, and expanding indications.
• Dominance remains with first-to-market products like eftrenonacog alfa, though biosimilars and emerging therapies threaten to reshape competition.
• Revenues are projected to reach hundreds of millions of dollars by 2030, with growth driven by geographic expansion, dosing convenience, and expanding patient populations.
• Pricing strategies, reimbursement policies, and biosimilar entry are critical variables influencing profitability.
• Opportunities exist in emerging markets, product innovation, and combination approaches, but regulatory and payor hurdles persist.

FAQs

Q1: How does Fc fusion extend factor IX half-life?
Fc fusion allows the biologic to engage neonatal Fc receptors, recycling the protein and reducing clearance, thereby extending half-life from approximately 18-24 hours to up to 7-14 days.

Q2: What are the main competitors to recombinant Fc fusion factor IX?
Non-factor therapies such as emicizumab, gene therapies, and other extended half-life factor IX products like non-Fc conjugates or pegylated variants.

Q3: What regions are expected to drive growth?
Emerging markets in Asia-Pacific, Latin America, and certain Middle Eastern countries, where diagnostic rates are rising, will significantly contribute to market expansion.

Q4: How do biosimilars impact the recombinant Fc fusion factor IX market?
Biosimilars, once approved, can reduce prices and increase access, but patent protections and manufacturing complexities can delay their impact.

Q5: What are future technological developments likely to influence this market?
Gene therapy advancements, improved biologic formulations, and combination treatments could redefine treatment paradigms and market shares.

---

References

[1] World Federation of Hemophilia, 2022 Report.
[2] FDA. "Eftrenonacog Alfa (ALPROLIX) Approval Summary," 2014.
[3] MarketWatch, "Hemophilia B Market Analysis," 2022.